UroGen Pharma Ltd. (URGN)

Market Cap	858.88M
Revenue (ttm)	94.24M
Net Income (ttm)	-154.97M
Shares Out	46.20M
EPS (ttm)	-3.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,825,999
Open	19.33
Previous Close	20.01
Day's Range	17.07 - 19.76
52-Week Range	3.42 - 21.02
Beta	1.13
Analysts	Strong Buy
Price Target	29.00 (+56.0%)
Earnings Date	Aug 7, 2025

About EDR

UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscl...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 4, 2017
• Employees: 235
• Stock Exchange: NASDAQ
• Ticker Symbol: URGN
• Website: https://www.urogen.com

Financial Performance

In 2024, UroGen Pharma's revenue was $90.40 million, an increase of 9.29% compared to the previous year's $82.71 million. Losses were -$126.87 million, 24.1% more than in 2023.

Analyst Summary

According to 8 analysts, the average rating for URGN stock is "Strong Buy." The 12-month stock price target is $29.0, which is an increase of 56.00% from the latest price.

Price Target

$29.0

(56.00% upside)

Analyst Consensus: Strong Buy